PMID- 34333058
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20220902
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 179
DP  - 2021 Sep
TI  - Association of plasma ceramides with prevalent and incident type 2 diabetes 
      mellitus in middle and older aged adults.
PG  - 108991
LID - S0168-8227(21)00350-8 [pii]
LID - 10.1016/j.diabres.2021.108991 [doi]
AB  - AIMS: The role of ceramides in the pathogenesis of type 2 diabetes mellitus 
      (T2DM) is incompletely characterized. Given that ceramides represent therapeutic 
      targets to disrupt the euglycemia-T2DM transition, we aimed to characterize their 
      association with prevalent and incident T2DM in a novel cohort. METHODS: We 
      examined the cross-sectional and longitudinal association of baseline ceramides 
      with prevalent and incident T2DM among 1423 adults (47% women; median (range) 
      baseline age 72 (51-95) years) in the Mayo Clinic Study of Aging cohort. We 
      examined the associations of ceramides with prevalent T2DM (adjusted odds ratio 
      [95% confidence interval]) at baseline and incident T2DM (adjusted hazard ratio 
      [95% confidence interval]) during median follow-up of 6.2 years, after adjusting 
      for demographic and metabolic factors. RESULTS: Among 1423 adults, there were 222 
      prevalent and 37 incident cases of T2DM. In cross-sectional analyses, higher 
      levels of ceramide C16:0 were associated with lower odds of prevalent T2DM (aOR 
      0.84 [0.71-0.99];P = 0.03) whereas C18:0 (aOR 1.27 [1.06-1.42];P = 0.01), 
      C18:0/16:0 (aOR 1.41 [1.22-1.62]; P < 0.001) and C18:0/24:0 (aOR 1.22 
      [1.05-1.41]; P = 0.01) were associated with higher odds. In Cox hazard regression 
      models, C18:0/16:0 (aHR 1.63 [1.26-2.10];P < 0.001) and C18:0 (aHR 1.53 
      [1.12-2.08];P = 0.01) were associated with increased risk of incident T2DM. 
      CONCLUSIONS: In this prospective population-based cohort, ceramides were 
      associated with prevalent T2DM (C16:0,C18:0, C18:0/C16:0 ratio, C18:0/C24:0 
      ratio) and incident T2DM (C18:0, C18:0/C16:0 ratio) and could suggest targets for 
      the primary and secondary prevention of T2DM.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Dugani, Sagar B
AU  - Dugani SB
AD  - Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, United 
      States; Division of Health Care Delivery Research, Kern Center for the Science of 
      Health Care Delivery, Mayo Clinic, Rochester, MN, United States.
FAU - Christenson, Luke R
AU  - Christenson LR
AD  - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United 
      States.
FAU - Aakre, Jeremiah A
AU  - Aakre JA
AD  - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United 
      States.
FAU - Bui, Hai H
AU  - Bui HH
AD  - Eli Lilly and Company, Indianapolis, IN, United States.
FAU - Vella, Adrian
AU  - Vella A
AD  - Division of Endocrinology, Mayo Clinic, Rochester, MN, United States.
FAU - Mielke, Michelle M
AU  - Mielke MM
AD  - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United 
      States; Department of Neurology, Mayo Clinic, Rochester, MN, United States. 
      Electronic address: mielke.michelle@mayo.edu.
LA  - eng
GR  - R01 AG034676/AG/NIA NIH HHS/United States
GR  - R01 AG049704/AG/NIA NIH HHS/United States
GR  - U01 AG006786/AG/NIA NIH HHS/United States
GR  - K23 MD016230/MD/NIMHD NIH HHS/United States
GR  - R33 AG058738/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20210729
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Ceramides)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ceramides
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC8478833
MID - NIHMS1730502
OTO - NOTNLM
OT  - Ceramides
OT  - Incident diabetes
OT  - Inflammation
OT  - Prevalent diabetes
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/08/02 06:00
MHDA- 2021/11/25 06:00
PMCR- 2022/09/01
CRDT- 2021/08/01 20:42
PHST- 2021/05/04 00:00 [received]
PHST- 2021/07/15 00:00 [revised]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/08/02 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/08/01 20:42 [entrez]
PHST- 2022/09/01 00:00 [pmc-release]
AID - S0168-8227(21)00350-8 [pii]
AID - 10.1016/j.diabres.2021.108991 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2021 Sep;179:108991. doi: 10.1016/j.diabres.2021.108991. 
      Epub 2021 Jul 29.